JP2013534227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534227A5 JP2013534227A5 JP2013524362A JP2013524362A JP2013534227A5 JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5 JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- nose
- powder
- ingested
- sucking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001331 nose Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010034699.3 | 2010-08-18 | ||
| DE102010034699A DE102010034699A1 (de) | 2010-08-18 | 2010-08-18 | Pyrimidinderivate |
| PCT/EP2011/003597 WO2012022408A1 (de) | 2010-08-18 | 2011-07-19 | Pyrimidinderivate als fak inhibitoren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016153334A Division JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534227A JP2013534227A (ja) | 2013-09-02 |
| JP2013534227A5 true JP2013534227A5 (https=) | 2016-01-07 |
| JP6049617B2 JP6049617B2 (ja) | 2016-12-21 |
Family
ID=44504442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524362A Expired - Fee Related JP6049617B2 (ja) | 2010-08-18 | 2011-07-19 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
| JP2016153334A Expired - Fee Related JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016153334A Expired - Fee Related JP6441861B2 (ja) | 2010-08-18 | 2016-08-04 | Ｆａｋ阻害剤としてのピリミジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8906916B2 (https=) |
| EP (1) | EP2606034B1 (https=) |
| JP (2) | JP6049617B2 (https=) |
| CN (1) | CN103052627B (https=) |
| AR (1) | AR082722A1 (https=) |
| AU (1) | AU2011291110B2 (https=) |
| CA (1) | CA2808540C (https=) |
| DE (1) | DE102010034699A1 (https=) |
| DK (1) | DK2606034T3 (https=) |
| ES (1) | ES2572740T3 (https=) |
| HR (1) | HRP20160562T1 (https=) |
| HU (1) | HUE027846T2 (https=) |
| IL (1) | IL224751A (https=) |
| PL (1) | PL2606034T3 (https=) |
| RS (1) | RS54882B1 (https=) |
| SI (1) | SI2606034T1 (https=) |
| WO (1) | WO2012022408A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
| HK1209104A1 (en) * | 2012-08-17 | 2016-03-24 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| CN104736533B (zh) * | 2012-08-17 | 2016-12-07 | 癌症治疗合作研究中心有限公司 | Vegfr3抑制剂 |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| WO2014174745A1 (ja) * | 2013-04-26 | 2014-10-30 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| US10106834B2 (en) | 2013-10-09 | 2018-10-23 | The General Hospital Corporation | Methods of diagnosing and treating B cell acute lymphoblastic leukemia |
| WO2015123722A1 (en) * | 2014-02-19 | 2015-08-27 | Bionomics Limited | Inhibitors |
| US10266549B2 (en) | 2014-08-25 | 2019-04-23 | Salk Institute For Biological Studies | ULK1 inhibitors and methods using same |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| WO2003087087A2 (en) | 2002-04-09 | 2003-10-23 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| CA2529611C (en) | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2006110763A1 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use for the treatment of cancer |
| EP2727909A1 (en) | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20130324532A1 (en) * | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9174946B2 (en) * | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
-
2010
- 2010-08-18 DE DE102010034699A patent/DE102010034699A1/de not_active Withdrawn
-
2011
- 2011-07-19 US US13/817,251 patent/US8906916B2/en not_active Expired - Fee Related
- 2011-07-19 JP JP2013524362A patent/JP6049617B2/ja not_active Expired - Fee Related
- 2011-07-19 EP EP11743438.1A patent/EP2606034B1/de active Active
- 2011-07-19 AU AU2011291110A patent/AU2011291110B2/en not_active Ceased
- 2011-07-19 HU HUE11743438A patent/HUE027846T2/en unknown
- 2011-07-19 RS RS20160420A patent/RS54882B1/sr unknown
- 2011-07-19 PL PL11743438T patent/PL2606034T3/pl unknown
- 2011-07-19 DK DK11743438.1T patent/DK2606034T3/en active
- 2011-07-19 ES ES11743438.1T patent/ES2572740T3/es active Active
- 2011-07-19 HR HRP20160562TT patent/HRP20160562T1/hr unknown
- 2011-07-19 CN CN201180039922.8A patent/CN103052627B/zh not_active Expired - Fee Related
- 2011-07-19 CA CA2808540A patent/CA2808540C/en not_active Expired - Fee Related
- 2011-07-19 SI SI201130848A patent/SI2606034T1/sl unknown
- 2011-07-19 WO PCT/EP2011/003597 patent/WO2012022408A1/de not_active Ceased
- 2011-08-18 AR ARP110102997A patent/AR082722A1/es unknown
-
2013
- 2013-02-17 IL IL224751A patent/IL224751A/en active IP Right Grant
-
2016
- 2016-08-04 JP JP2016153334A patent/JP6441861B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534227A5 (https=) | ||
| JP2014509313A5 (https=) | ||
| JP2014526447A5 (https=) | ||
| JP2013544781A5 (https=) | ||
| JP2013541565A5 (https=) | ||
| JP2015505541A5 (https=) | ||
| Weber et al. | Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art | |
| Doktorovova et al. | Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation | |
| JP2013538214A5 (https=) | ||
| RU2015121091A (ru) | Порошки для ингаляции с ультранизкой плотностью | |
| EA201590286A1 (ru) | Аэрозольное ингаляционное устройство | |
| BR112013022249B8 (pt) | Dispositivo de distribuição de droga nasal | |
| CL2013000153A1 (es) | Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo. | |
| WO2014012069A3 (en) | Dry powder drug delivery systems and methods | |
| JP2017502064A5 (https=) | ||
| ATE527976T1 (de) | Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes | |
| EA201591729A1 (ru) | Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства | |
| WO2010029441A3 (en) | Nasal delivery | |
| JP2020527377A5 (https=) | ||
| WO2005084638A3 (en) | Formulations decreasing infectivity of pulmonary diseases | |
| JP2014528470A5 (https=) | ||
| WO2012024595A3 (en) | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain | |
| EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб |